Table 1

Patient demographics and baseline characteristics

All patientsBCLC-B2 substageUnilobar tumors with portal vein invasion
Patients (n, %)42 (100)31 (73.8)11 (26.2)
Males (n, %)36 (85.7)27 (87.1)9 (81.1)
Age in years (median, IQR)65 (49–79)65 (49–79)65 (55–79)
Vascular invasion (n, %)11 (26.2)011 (100)
BCLC stage (n, %)
A3 (7.1)3 (9.7)0
B25 (59.6)25 (80.6)0
C14 (33.3)3 (9.7)11 (100)
Etiology (n, %)
Uninfected32 (76.2)25 (80.6)7 (63.6)
Hepatitis C9 (21.4)5 (16.1)4 (36.4)
Hepatitis B1 (2.4)1 (3.2)0
Alcohol consumption (n, %)5 (11.9)3 (9.6)2 (18.1)
Arterial hypertension (n, %)20 (47.6)16 (51.6)4 (36.4)
Diabetes (n, %)10 (23.8)7 (22.6)3 (27.3)
Dyslipidemia (n, %)9 (21.4)8 (25.8)1 (9.1)
ECOG performance status (n, %)
038 (90.5)28 (90.3)10 (90.9)
14 (9.5)3 (9.7)1 (9.1)
Child-Pugh class (n, %)
A536 (85.7)27 (87.1)9 (81.8)
A66 (14.3)4 (12.9)2 (18.2)
ALBI grade (n, %)
121 (50)17 (54.9)4 (36.4)
221 (50)14 (45.1)7 (63.6)
Previous treatment (n, %)
Liver resection7 (16.7)5 (16.1)2 (18.2)
Percutaneous ablation6 (14.3)5 (16.1)1 (9.1)
TACE11 (26.2)11 (35.5)0
Sorafenib6 (14.3)5 (16.1)1 (9.1)
Alpha-fetoprotein >400 ng/mL (n, %)12 (29.3)7 (23.3)5 (45.5)
Platelet count, /pL (median, IQR)141 (46–512)139 (46–512)145 (59–288)
Total bilirubin, mg/dL (median, IQR)0.76 (0.20–1.89)0.72 (0.20–1.89)0.90 (0.40–1.40)
Albumin, g/dL (median, IQR)3.95 (3.00–4.80)4.00 (3.00–4.80)3.83 (3.20–4.80)
Neutrophil to lymphocyte ratio (median, IQR)2.69 (1.86–4.25)2.61 (1.83–4.15)3.38 (1.87–4.34)
  • ALBI, Albumin-Bilirubin; BCLC, Barcelona Clinic Liver Cancer; ECOG, Eastern Cooperative Oncology Group; TACE, Transarterial chemoembolization.